SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Atos SE (AEXAY) , forward earnings yield 5.73%. PEG 0.16 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
- Forward P/E 17.5
- PEG Ratio 0.16 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
Overall SharesGrow Score: 22/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
HEALTH
25/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — AEXAY
Valuation Multiples
P/E (TTM)0.0
Forward P/E17.5
PEG Ratio0.16
Forward PEG0.16
P/B Ratio0.00
P/S Ratio0.11
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-13.89
Forward EPS (Est.)$0.52
Book Value / Share$0.00
Revenue / Share$79.18
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield5.73%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$0.22 |
$11.72B |
$578.8M |
4.9% |
| 2017 |
$0.23 |
$12.69B |
$601M |
4.7% |
| 2018 |
$0.24 |
$12.26B |
$630M |
5.1% |
| 2019 |
$0.69 |
$11.59B |
$370M |
3.2% |
| 2020 |
$1.01 |
$11.18B |
$550M |
4.9% |
| 2021 |
$-5.40 |
$10.84B |
$-2.96B |
-27.3% |
| 2022 |
$-1.84 |
$11.34B |
$-1.02B |
-9% |
| 2023 |
$-0.05 |
$10.69B |
$-3.44B |
-32.2% |
| 2024 |
$12.40 |
$9.58B |
$248M |
2.6% |
| 2025 |
$-13.89 |
$7.69B |
$-1.35B |
-17.5% |
